Desensitization for hypersensitivity reactions to medications

Chemical Immunology and Allergy

Volumn 97, Issue , 2012, Pages 217-233

  Del Carmen Sancho, Maria ^a   Breslow, Rebecca ^a   Sloane, David ^a   Castells, Mariana ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTIRETROVIRUS AGENT; BASILIXIMAB; CARBOPLATIN; CEPHALOSPORIN; CETUXIMAB; CISPLATIN; COTRIMOXAZOLE; DOCETAXEL; IMMUNOGLOBULIN E; INFLIXIMAB; ISONIAZID; METRONIDAZOLE; MONOCLONAL ANTIBODY; NATALIZUMAB; OMALIZUMAB; OXALIPLATIN; PACLITAXEL; PENICILLIN G; TAXANE DERIVATIVE; TRASTUZUMAB; VANCOMYCIN;

ANAPHYLAXIS; ARTICLE; DESENSITIZATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; RAPID DRUG DESENSITIZATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS; ANTINEOPLASTIC AGENTS; CALCIUM; CISPLATIN; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; IMMUNOGLOBULIN E; INFLAMMATION MEDIATORS; MAST CELLS; MICE; NEOPLASMS; RECEPTORS, IGE; TAXOIDS;

EID: 84926084736     PISSN: 16602242     EISSN: 16622898     Source Type: Book Series    
DOI: 10.1159/000335637     Document Type: Article

References (62)

1. Schwartz LB, Metcalfe DD, Miller JS, et al: Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987;316:1622-1626.
2. Vadas P, Gold M, Perelman B, et al: Plateletactivating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008;358:28-35.
3. Castells M: Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006;6:476-481.
4. Lee CW, Matulonis UA, Castells MC: Rapid inpatient/ outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005;99: 393-399.
5. Castells MC, Tennant NM, Sloane DE, et al: Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574-580.
6. Lee CW, Matulonis UA, Castells MC: Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004;95:370-376.
7. Kraft S, Kinet JP: New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007;7:365-378.
8. Gilfillan AM, Rivera J: The tyrosine kinase network regulating mast cell activation. Immunol Rev 2009; 228:149-169.
9. Shalit M, Levi-Schaffer F: Challenge of mast cells with increasing amounts of antigen induces desensitization. Clin Exp Allergy 1995;25:896-902.
10. Kepley CL: Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels. Int Arch Allergy Immunol 2005; 138:29-39.
11. Morales AR, Shah N, Castells M: Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol 2005;94:575-580.
12. Wendel GD Jr, Stark BJ, Jamison RB, Molina RD, Sullivan TJ: Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985;312:1229-1232.
13. Gadde J, Spence M, Wheeler B, Adkinson NF Jr: Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA 1993;270:2456-2463.
14. Green GR, Rosenblum AH, Sweet LC: Evaluation of penicillin hypersensitivity: value of clinical history and skin testing with penicilloyl-polylysine and penicillin G. A cooperative prospective study of the penicillin study group of the American Academy of Allergy. J Allergy Clin Immunol 1977;60:339-345.
15. Park MA, Li JT: Diagnosis and management of penicillin allergy. Mayo Clin Proc 2005;80:405-410.
16. Salkind AR, Cuddy PG, Foxworth JW: The rational clinical examination. Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy. JAMA 2001;285:2498-2505.
17. Sogn DD, Evans R 3rd, Shepherd GM, et al: Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med 1992;152:1025-1032.
18. Park MA, Koch CA, Klemawesch P, Joshi A, Li JT: Increased adverse drug reactions to cephalosporins in penicillin allergy patients with positive penicillin skin test. Int Arch Allergy Immunol 2010;153: 268-273.
19. Kelkar PS, Li JT: Cephalosporin allergy. N Engl J Med 2001;345:804-809.
20. Saxon A, Adelman DC, Patel A, Hajdu R, Calandra GB: Imipenem cross-reactivity with penicillin in humans. J Allergy Clin Immunol 1988;82:213-217.
21. Romano A, Viola M, Gueant-Rodriguez RM: Imipenem in patients with immediate hypersensitivity to penicillins. N Engl J Med 2006;354: 2835-2837.
22. Burrows JA, Toon M, Bell SC: Antibiotic desensitization in adults with cystic fibrosis. Respirology 2003;8:359-364.
23. Legere HJ 3rd, Palis RI, Rodriguez Bouza T, et al: A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros 2009;8:418-424.
24. Turvey SE, Cronin B, Arnold AD, Dioun AF: Antibiotic desensitization for the allergic patient: 5 years of experience and practice. Ann Allergy Asthma Immunol 2004;92:426-432.
25. Fruman DA, Wood MA, Gjertson CK, et al: FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. Eur J Immunol 1900;25:563-571.
26. Renz CL, Laroche D, Thurn JD, et al: Tryptase levels are not increased during vancomycin-induced anaphylactoid reactions. Anesthesiology 1998;89: 620-625.
27. Anne S, Middleton E Jr, Reisman RE: Vancomycin anaphylaxis and successful desensitization. Ann Allergy 1994;73:402-404.
28. Kitazawa T, et al: Successful vancomycin desensitization with a combination of rapid and slow infusion methods. Intern Med 2006;45:317-321.
29. Lin RY: Desensitization in the management of vancomycin hypersensitivity. Arch Intern Med 1990; 150:2197-2198.
30. Wazny LD, Daghigh B: Desensitization protocols for vancomycin hypersensitivity. Ann Pharmacother 2001;35:1458-1464.
31. Wong JT, Ripple RE, MacLean JA, et al: Vancomycin hypersensitivity: synergism with narcotics and 'desensitization' by a rapid continuous intravenous protocol. J Allergy Clin Immunol 1994;94:189-194.
32. Gea-Banacloche JC, Metcalfe DD: Ciprofloxacin desensitization. J Allergy Clin Immunol 1996;97: 1426-1427.
33. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W: Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986;105:179-184.
34. Earl HS, Sullivan TJ: Acute desensitization of a patient with cystic fibrosis allergic to both beta-lactam and aminoglycoside antibiotics. J Allergy Clin Immunol 1987;79:477-483.
35. Spigarelli MG, Hurwitz ME, Nasr SZ: Hypersensitivity to inhaled TOBI following reaction to gentamicin. Pediatr Pulmonol 2002;33:311-314.
36. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-2666.
37. Kwon JS, Elit L, Finn M, et al: A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 2002;84:420-425.
38. Markman M, Kennedy A, Webster K, et al: Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000;18:102-105.
39. Wiernik PH, Schwartz EL, Strauman JJ, et al: Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987;47:2486-2493.
40. Schrijvers D, Wanders J, Dirix L, et al: Coping with toxicities of docetaxel (Taxotere). Ann Oncol 1993; 4:610-611.
41. Weiss RB, Donehower RC, Wiernik PH, et al: Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-1268.
42. Price KS, Castells MC: Taxol reactions. Allergy Asthma Proc 2002;23:205-208.
43. Decorti G, Bartoli Klugmann F, Candussio L, Baldini L: Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin. Anticancer Res 1996;16:317-320.
44. Eschalier A, Lavarenne J, Burtin C, et al: Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 1988;21:246-250.
45. Essayan DM, Kagey-Sobotka A, Colarusso PJ, et al: Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 1996;97:42-46.
46. Szebeni J, Muggia FM, Alving CR: Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90:300-306.
47. Feldweg AM, Lee CW, Matulonis UA, Castells M: Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 2005;96:824-829.
48. Aabo K, Adnitt P, Alberts DS, Athanazziou A, et al: Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998;78: 1479-1487.
49. Gomez R, Harter P, Luck HJ, et al: Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int J Gynecol Cancer 2009;19:1284-1287.
50. Gadducci A, Tana R, Teti G, et al: Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008;18: 615-620.
51. Makrilia N, Syrigou E, Kaklamanos I, et al: Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 2010;ii:207084.
52. Markman M, Kennedy A, Webster K, et al: Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999;17:1141.
53. Maindrault-Goebel F, Andre T, Tournigand C, et al: Allergic-type reactions to oxaliplatin: retrospec tive analysis of 42 patients. Eur J Cancer 2005;41: 2262-2267.
54. Lee C, Gianos M, Klaustermeyer WB: Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009;102:179-187, quiz 187-189, 222.
55. Schwartz JR, Bandera C, Bradley A, et al: Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. Gynecol Oncol 2007;105:81-83.
56. Polyzos A, Tsavaris N, Kosmas C, et al: Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001;61:129-133.
57. Dizon DS, Sabbatini PJ, Aghajanian C, et al: Analysis of Patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002;84:378-382.
58. Chung CH, O'Neil BH: Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors. Oncology (Williston Park) 2009;23:14-17.
59. Brennan PJ, Rodriguez Bouza T, et al: Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009;124:1259-1266.
60. Brown SG: Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004;114: 371-376.
61. Breslow RG, Caiado J, Castells MC: Acetylsalicylic acid and montelukast block mast cell mediatorrelated symptoms during rapid desensitization. Ann Allergy Asthma Immunol 2009;102:155-160.
62. Sancho-Serra M, Simarro M, Castells M: Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FceRI internalization. Eur J Immunol 2011;41:1004-1013.